{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:30:16Z","timestamp":1786437016245,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"IAS-CIPHER","award":["CIPHER-ADOLA-2023"],"award-info":[{"award-number":["CIPHER-ADOLA-2023"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,16]]},"abstract":"<jats:p>\n                    Achieving and maintaining viral suppression (VS) in pediatric populations remain suboptimal in low- and middle-income countries (LMICs), calling for the optimized management approaches. We compared the rate of confirmed virological failure (cVF) and associated factors among virally non-suppressed (VnS) children and adolescents after enhanced adherence counseling (EAC) on dolutegravir-based versus other regimens. A multicentre and prospective cohort study was conducted among ART-experienced children (&lt;10 years) and adolescents (10\u201319 years) with VnS followed-up for confirmatory viral load (VL) after EAC. cVF was defined as 2 consecutive VL\u2005\u2265\u20051000 copies\/mL after \u22656 months of ART and EAC. Overall, 250 individuals with VnS were enrolled, median [IQR] age was 12 (11\u201313) and median duration on ART was 57 (48\u201367) months. According to ART-regimens, 48.4% received DTG-based regimens (TDF\/3TC\/DTG: 32.8%; ABC\/3TC\u2005+\u2005DTG: 15.6%). Overall, cVF rate was 39.2% (95% CI: 33.3\u201345.3), with a longer duration on ART among cVF-group (68 [60\u201379] months) versus VS-group (48 [45\u201361]),\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.026. According to ART-regimen, cVF rate was 29.3% in those receiving TDF\/3TC\/DTG versus 43.5% for ABC\/3TC\u2005+\u2005ATV\/r\/LPV\/r and 25.6% for ABC\/3TC\u2005+\u2005DTG,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.007. Regarding anchor-drugs, cVF with DTG, EFV and ATV\/r\/LPV\/r was 28.1%, 48.4% and 49.2%, respectively,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.007. Interestingly, 13.2% of participants with VS had detectable low-level viremia (400\u2013999 copies\/mL), with 5.8%, 7.7% and 12.9% being observed in those receiving DTG, ATV\/r\/LPV\/r, and EFV\/NVP-based regimen, respectively,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.013. Only anchor-drug was found to be a predictor of cVF. Compared to those receiving DTG-based regimens, ART based on ATV\/LPV\/r (aOR [95% CI]: 0.298 [0.132\u20130.72],\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.004) or EFV\/NVP (aOR [95% CI]: 0.401 [0.163\u20130.983],\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.046) was significantly less likely to achieve VS. About 40% of Cameroonian children\/adolescents with VnS experience cVF, which is indicative that EAC significantly contributes to viral re-suppression (60%), especially with DTG-based regimens. Thus, implementing a strategy that couples DTG-transition with EAC-interventions would contribute substantially to efforts in eliminating pediatric AIDS in LMICs.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000042555","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T14:01:35Z","timestamp":1747836095000},"page":"e42555","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Confirmed virological failure following enhanced adherence counseling among virally unsuppressed children and adolescents on dolutegravir-based versus other regimens: Evidence from a cohort analysis in Cameroon"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4187-683X","authenticated-orcid":false,"given":"Yagai","family":"Bouba","sequence":"first","affiliation":[{"name":"Departmental Faculty of Medicine and Surgery, Saint Camillus International University of Health Sciences, Rome, Italy"},{"name":"Virology Laboratory, Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude Christelle","family":"Ka\u2019e","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davy-Hyacinthe","family":"Anguechia Gouissi","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Ayafor","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Tameza Guebiapsi","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Martin","family":"Sosso","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Simo Kamgaing","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzie","family":"Ndiang Tetang","sequence":"additional","affiliation":[{"name":"Pediatric Department, Essos Health Centre, National Social Welfare Centre, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzane","family":"Essamba","sequence":"additional","affiliation":[{"name":"Central Technical Group, National AIDS Control Committee (NACC), Ministry of Public Health, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Kamgaing","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Ndejo Atsinkou","sequence":"additional","affiliation":[{"name":"Central Technical Group, National AIDS Control Committee (NACC), Ministry of Public Health, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Ketchaji","sequence":"additional","affiliation":[{"name":"Division of Diseases, HIV\/AIDS Department, Epidemic and Pandemic Control, Ministry of Public Health, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Durand","family":"Nka","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Nguendjoung Fainguem","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel Carlos","family":"Tommo Tchouaket","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desir\u00e9","family":"Takou","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezechiel","family":"Jagni Semengue Ngoufack","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Amougou Atsama","sequence":"additional","affiliation":[{"name":"Laboratory of Virology, Research Center on Emerging and Re-Emerging Diseases (CREMER),Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Nwobegahay","sequence":"additional","affiliation":[{"name":"Centre for Research and Military Health (CRESAR), Ministry of Defense, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Eyoum Bille","sequence":"additional","affiliation":[{"name":"Retrovirology Laboratory, Laquintinie Hospital, Douala, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Gatchuessi Kenmegne","sequence":"additional","affiliation":[{"name":"Molecular Biology Laboratory, Fondation Sociale Suisse, Pette Hospital, Pette, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ateba Ndongo","sequence":"additional","affiliation":[{"name":"HIV\/AIDS Treatment Centre, Mother-Child Centre, Chantal BIYA Foundation, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicit\u00e9","family":"Noukayo","sequence":"additional","affiliation":[{"name":"HIV\/AIDS Treatment Centre, Cit\u00e9 Verte District Hospital, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogers","family":"Awoh Ajeh","sequence":"additional","affiliation":[{"name":"Global Funds Subvention Coordination Unit, Ministry of Public Health, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadja","family":"Cherif Hamsatou","sequence":"additional","affiliation":[{"name":"Central Technical Group, National AIDS Control Committee (NACC), Ministry of Public Health, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ndie","sequence":"additional","affiliation":[{"name":"Division of Operational Research in Health, Ministry of Public Health, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yembe","family":"Wepnyu Njamnshi","sequence":"additional","affiliation":[{"name":"Division of Operational Research in Health, Ministry of Public Health, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicit\u00e9","family":"Naah","sequence":"additional","affiliation":[{"name":"Division of Operational Research in Health, Ministry of Public Health, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Cecile","family":"Zoung-Kanyi Bissek","sequence":"additional","affiliation":[{"name":"Division of Operational Research in Health, Ministry of Public Health, Yaound\u00e9, Cameroon"},{"name":"Faculty of Medicine and Biomedical Sciences, University of Yaound\u00e9 I, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge Clotaire","family":"Billong","sequence":"additional","affiliation":[{"name":"Division of Diseases, HIV\/AIDS Department, Epidemic and Pandemic Control, Ministry of Public Health, Yaound\u00e9, Cameroon"},{"name":"Faculty of Medicine and Biomedical Sciences, University of Yaound\u00e9 I, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Koki Ndombo","sequence":"additional","affiliation":[{"name":"HIV\/AIDS Treatment Centre, Mother-Child Centre, Chantal BIYA Foundation, Yaound\u00e9, Cameroon"},{"name":"Faculty of Medicine and Biomedical Sciences, University of Yaound\u00e9 I, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chatte","family":"Adawaye","sequence":"additional","affiliation":[{"name":"Global Funds Project Management Unit, Republic of Chad, N\u2019djamena, Chad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Cappelli","sequence":"additional","affiliation":[{"name":"Institute for Biological Systems (ISB), National Research Council, Rome, Italy"},{"name":"Laboratoire de Lutte contre les Grandes End\u00e9mies (LAGET), Centre Hospitalo-Universitaire le Bon Samaritain, N\u2019djamena, Chad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory-Edie","family":"Ekane Halle","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of Buea, Buea, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Armenia","sequence":"additional","affiliation":[{"name":"Departmental Faculty of Medicine and Surgery, Saint Camillus International University of Health Sciences, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Mercedes","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome \u201cTor Vergata\u201d, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome \u201cTor Vergata\u201d, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicaise","family":"Ndembi","sequence":"additional","affiliation":[{"name":"Division of Surveillance and Disease Intelligence, Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia"},{"name":"Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ndjolo","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"Faculty of Medicine and Biomedical Sciences, University of Yaound\u00e9 I, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Colizzi","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"Laboratoire de Lutte contre les Grandes End\u00e9mies (LAGET), Centre Hospitalo-Universitaire le Bon Samaritain, N\u2019djamena, Chad"},{"name":"UNESCO Board of Multidisciplinary Biotechnology, University of Rome \u201cTor Vergata\u201d, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo-Federico","family":"Perno","sequence":"additional","affiliation":[{"name":"Microbiology and Diagnostic Immunology Unit, Bambino Ges\u00f9\u2019 Children Hospital, IRCCS, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Fokam","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"Central Technical Group, National AIDS Control Committee (NACC), Ministry of Public Health, Yaound\u00e9, Cameroon"},{"name":"Faculty of Health Sciences, University of Buea, Buea, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260811","article-title":"HIV\/AIDS fact sheet","year":"2021"},{"key":"R3-20260811","article-title":"Adolescent HIV treatment \u2013 July 2023 Update."},{"key":"R4-20260811"},{"key":"R5-20260811","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12981-019-0252-0","article-title":"Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: adolescents at high risk of virological failure in the era of \u201ctest and treat.\u201d.","volume":"16","author":"Fokam","year":"2019","journal-title":"AIDS Res Ther"},{"key":"R6-20260811","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40471-021-00268-3","article-title":"HIV drug resistance in children and adolescents: always a challenge?","volume":"8","author":"Koay","year":"2021","journal-title":"Curr Epidemiol Rep"},{"key":"R7-20260811","doi-asserted-by":"crossref","first-page":"20683","DOI":"10.7448\/IAS.19.1.20683","article-title":"High rates of virological failure and drug resistance in perinatally HIV\u20101\u2010infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo.","volume":"19","author":"Salou","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"R8-20260811","first-page":"93","article-title":"Adherence to HIV care and associated health functioning among youth living with HIV in Sub-Saharan Africa.","volume":"22","author":"Tarantino","year":"2021","journal-title":"AIDS Rev"},{"key":"R9-20260811","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/hiv.13095","article-title":"Alarming rates of virological failure and HIV-1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY-study in Cameroon.","volume":"22","author":"Fokam","year":"2021","journal-title":"HIV Med"},{"key":"R10-20260811","first-page":"1035","article-title":"Determinants of virological failure among HIV-infected children on first-line antiretroviral therapy in West Gojjam Zone, Amhara Region, Ethiopia.","volume":"13","author":"Shumetie","year":"2021","journal-title":"HIV AIDS (Auckl)"},{"key":"R11-20260811","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/INF.0000000000002288","article-title":"HIV-1 drug resistance and virologic outcomes among tanzanian youth living with HIV.","volume":"38","author":"Dow","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R12-20260811","article-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach."},{"key":"R13-20260811","doi-asserted-by":"crossref","first-page":"e36777","DOI":"10.1371\/journal.pone.0036777","article-title":"Early warning indicators for HIV drug resistance in cameroon during the Year 2010.","volume":"7","author":"Billong","year":"2012","journal-title":"PLoS One"},{"key":"R14-20260811","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12887-019-1599-z","article-title":"Evaluation of treatment response, drug resistance and HIV-1 variability among adolescents on first- And second-line antiretroviral therapy: a study protocol for a prospective observational study in the centre region of Cameroon (EDCTP READY-study).","volume":"19","author":"Fokam","year":"2019","journal-title":"BMC Pediatr"},{"key":"R15-20260811","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1093\/jac\/dkac338","article-title":"Pre-treatment HIV-1 drug resistance in antiretroviral therapy-naive adults in Eastern Africa: a systematic review and meta-analysis.","volume":"77","author":"Ntamatungiro","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R16-20260811","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jclinepi.2022.02.005","article-title":"Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: systematic review and Bayesian evidence synthesis.","volume":"148","author":"Hauser","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"R17-20260811","doi-asserted-by":"crossref","first-page":"e33737","DOI":"10.1097\/MD.0000000000033737","article-title":"Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: children at high risk of virological failure due to the lowly transition in pediatrics.","volume":"102","author":"Fokam","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"R18-20260811","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12887-023-03943-0","article-title":"Viral load suppression in HIV-infected adolescents in cameroon: towards achieving the UNAIDS 95% viral suppression target.","volume":"23","author":"Djiyou","year":"2023","journal-title":"BMC Pediatr"},{"key":"R19-20260811","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/jpids\/piy139","article-title":"Long-term safety and efficacy of dolutegravir in treatment-experienced adolescents with human immunodeficiency virus infection: results of the impaact P1093 study.","volume":"9","author":"Viani","year":"2020","journal-title":"J. Pediatric Infect. Dis. Soc"},{"key":"R20-20260811","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1016\/S2352-3018(20)30189-2","article-title":"Simplified dolutegravir dosing for children with HIV weighing 20\u2009kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.","volume":"7","author":"Bollen","year":"2020","journal-title":"Lancet HIV"},{"key":"R21-20260811","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2352-3018(21)00292-7","article-title":"Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.","volume":"9","author":"Waalewijn","year":"2022","journal-title":"Lancet HIV"},{"key":"R22-20260811","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0213-005X(15)30006-9","article-title":"Efficacy of dolutegravir in treatment-experienced patients: The SAILING and VIKING trials.","volume":"33","author":"Moreno","year":"2015","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"R23-20260811","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"R24-20260811","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.","volume":"19","author":"Aboud","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R25-20260811","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"R26-20260811","doi-asserted-by":"crossref","first-page":"104534","DOI":"10.1016\/j.jcv.2020.104534","article-title":"Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings.","volume":"130","author":"Armenia","year":"2020","journal-title":"J Clin Virol"},{"key":"R27-20260811","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2989\/16085906.2021.1998783","article-title":"Antiretroviral therapy adherence and viral suppression among HIV-infected adolescents and young adults at a tertiary hospital in Ghana.","volume":"20","author":"Biney","year":"2021","journal-title":"African J AIDS Res"},{"key":"R28-20260811","doi-asserted-by":"crossref","first-page":"e0291487","DOI":"10.1371\/journal.pone.0291487","article-title":"Barriers and facilitators to ART adherence among ART non-adherence people living with HIV in cameroon: a qualitative phenomenological study.","volume":"18","author":"Buh","year":"2023","journal-title":"PLoS One"},{"key":"R29-20260811","doi-asserted-by":"crossref","first-page":"e0000826","DOI":"10.1371\/journal.pgph.0000826","article-title":"HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis.","volume":"2","author":"Semengue","year":"2022","journal-title":"PLOS Global Public Health"},{"key":"R30-20260811","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3390\/v15071458","article-title":"Pre-treatment HIV drug resistance and genetic diversity in cameroon: implications for first-line regimens.","volume":"15","author":"Fokam","year":"2023","journal-title":"Viruses"},{"key":"R31-20260811","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.3390\/biomedicines12092083","article-title":"Evaluation of viral suppression in paediatric populations: implications for the transition to dolutegravir-based regimens in cameroon: the CIPHER-ADOLA study.","volume":"12","author":"Fokam","year":"2024","journal-title":"Biomedicines"},{"key":"R32-20260811","doi-asserted-by":"crossref","first-page":"e0129210","DOI":"10.1371\/journal.pone.0129210","article-title":"Monitoring HIV drug resistance early warning indicators in Cameroon: a study following the revised world health organization recommendations.","volume":"10","author":"Fokam","year":"2015","journal-title":"PLoS One"},{"key":"R33-20260811","doi-asserted-by":"crossref","first-page":"e0000418","DOI":"10.1371\/journal.pgph.0000418","article-title":"Factors associated with antiretroviral therapy adherence among adolescents living with HIV in the era of isoniazid preventive therapy as part of HIV care.","volume":"2","author":"Villiera","year":"2022","journal-title":"PLOS Global Public Health"},{"key":"R34-20260811","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13052-018-0469-x","article-title":"Dolutegravir-based anti-retroviral therapy is effective and safe in HIV-infected paediatric patients.","volume":"44","author":"Bruzzese","year":"2018","journal-title":"Ital J Pediatr"},{"key":"R35-20260811","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/v15010018","article-title":"Dolutegravir-based regimen ensures high virological success despite prior exposure to efavirenz-based first-LINE ART in Cameroon: an evidence of a successful transition model.","volume":"15","author":"Semengue","year":"2022","journal-title":"Viruses"},{"key":"R36-20260811","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2174\/1381612823666170329142059","article-title":"Recent advances in antiretroviral agents: potent integrase inhibitors.","volume":"23","author":"Psichogiou","year":"2017","journal-title":"Curr Pharm Des"},{"key":"R37-20260811","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/1060028013513558","article-title":"Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.","volume":"48","author":"Rathbun","year":"2014","journal-title":"Ann Pharmacother"},{"key":"R38-20260811","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4314\/ahs.v21i1.4S","article-title":"Factors affecting adherence to antiretroviral therapy among children and adolescents living with HIV in the Mbita Sub County Hospital, Homa Bay\u2013 Kenya.","volume":"21","author":"Tanyi","year":"2021","journal-title":"Afr Health Sci"},{"key":"R39-20260811","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4236\/ijcm.2019.103011","article-title":"Impact of therapeutic education on the viral load of HIV infected children and adolescents on antiretroviral therapy at the Douala Laquintinie Hospital, Cameroon.","volume":"10","author":"Ida Penda","year":"2016","journal-title":"Int J Clin Med"},{"key":"R40-20260811","doi-asserted-by":"crossref","first-page":"e0289426","DOI":"10.1371\/journal.pone.0289426","article-title":"High risk of virologic failure among HIV-infected children and adolescents routinely followed-up in Littoral region of Cameroon.","volume":"18","author":"Mb\u00e9bi Enon\u00e9","year":"2023","journal-title":"PLoS One"},{"key":"R41-20260811","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1473-3099(24)00289-5","article-title":"Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.","volume":"24","author":"Kityo","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"R42-20260811","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12981-021-00391-7","article-title":"Determinants of viral suppression among adolescents on antiretroviral treatment in Ehlanzeni district, South Africa: a cross-sectional analysis.","volume":"18","author":"Okonji","year":"2021","journal-title":"AIDS Res Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:01:27Z","timestamp":1786435287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":41,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042555","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]}}}